Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
Caris Life Sciences, Inc. incurred credit facility of $400,000,000 initial term loan, up to $300,000,000 delayed draw facility, and up to $500,000,000 uncommitted incremental with Blue Owl Capital and Blackstone at Term SOFR Rate or Base Rate plus 5.00% or 4.00%, respectively maturing Initial Term Facility matures in April 2031; Delayed Draw Facility available through August 2027.
- Instrument
- credit facility
- Principal
- $400,000,000 initial term loan, up to $300,000,000 delayed draw facility, and up to $500,000,000 uncommitted incremental
- Counterparty
- Blue Owl Capital and Blackstone
- Rate
- Term SOFR Rate or Base Rate plus 5.00% or 4.00%, respectively
- Maturity
- Initial Term Facility matures in April 2031; Delayed Draw Facility available through August 2027
- Event
- incurrence
Exact text from the filing
On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Caris Life Sciences, Inc. entered into New Credit Agreement with Blue Owl Capital and Blackstone valued at Senior secured credit facilities: $400M initial term loan, $300M delayed draw, $500M incremental fac (effective 2026-04-01).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Blue Owl Capital and Blackstone
- Value
- Senior secured credit facilities: $400M initial term loan, $300M delayed draw, $500M incremental fac
- Effective
- 2026-04-01
Exact text from the filing
On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Caris Life Sciences, Inc. terminated Previous Credit Agreement with Wilmington Trust, National Association valued at Repaid all outstanding indebtedness and terminated guarantees, liens, and security interests under t (effective 2026-04-01).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- Wilmington Trust, National Association
- Value
- Repaid all outstanding indebtedness and terminated guarantees, liens, and security interests under t
- Effective
- 2026-04-01
Exact text from the filing
On the Closing Date, the Company used proceeds under the Initial Term Facility to repay all outstanding indebtedness under that certain credit agreement, dated as of January 18, 2023, by and among the Company, certain of the Company’s subsidiaries, the lenders from time to time party thereto and Wilmington Trust, National Association, as administrative agent, as amended (the “ Previous Credit Agreement ”). The Company terminated all guarantees, liens and other security interests granted under and terminated the Previous Credit Agreement.
View on SEC.gov